J. E. Davis

CEO Davis sold 10,000 DGX shares at $194.14 under pre-arranged 10b5-1 plan

J. E. Davis, who was CEO at the time of this transaction, sold 10,000 shares (132.4K shares remaining post-sale) on 2026-06-01 at $194.14 per share for a total of $1,941,400.00 under a pre-arranged 10b5-1 trading plan, meaning this was a scheduled transaction rather than a discretionary decision. His prior sales at DGX show mixed near-term performance: the most recent prior sale on 2026-03-02 saw 30d returns of -7.0% and 90d returns of -8.3%, while other sales in November 2025 exhibited 30-day declines ranging from -8.2% to -8.8% before recovering to positive 90-day returns. The stock currently trades at $193.16, down -9.5% from its 52-week high of $213.50 and down -7.3% over the trailing 90 days, reflecting broader price weakness in the security since this sale occurred.

CEO Davis J. E. sold 10,000 DGX shares at $212.52; holdings now 117.2K. Prior DGX sales poorly timed (avg +7.9–8.3% 90d return).

Davis J. E. sold 10,000 shares (7.9% of pre-transaction holdings) at $212.52, reducing his position to 117.2K shares. The sale occurred near the 52-week high of $211.91 and the stock has gained 12.7% over 30 days and 13.2% over 90 days from the transaction date. His prior five trades at DGX have all resulted in positive 90-day returns ranging from +7.5% to +8.3%, indicating poor timing on those sells (the stock rose after each one). His cross-ticker track record shows a 0.00% well-timed rate across 18 prior sells, though with modest average 90-day returns of +6.5%. The company's fundamentals remain solid with quarterly revenue of $2,816,000,000.00 and net income of $245,000,000.00, plus 11.8% annual revenue growth. This sale continues a pattern of poorly-timed exits at this ticker rather than suggesting imminent operational concern.

CEO Davis sells 55,093 shares at $192.22 avg for $10.6M; retains 120,480 shares post-sale

Davis J. E., CEO and President of Quest Diagnostics, executed 3 separate sales on 2025-11-25 totaling 55,093 shares for $10,589,759.82 at a blended average price of $192.22, reducing his holdings by 31.4%. His cross-ticker track record shows 15 prior sells with a 90-day well-timed rate of 0.00%, and his prior 5 DGX trades at this ticker (all on 2025-04-02) were similarly not well-timed, with subsequent 90-day returns ranging from +5.7% to +6.8%, indicating he sold before gains materialized in prior instances. The current stock price of $189.18 is 1.6% below the 52-week high of $192.35, and the company is trading at a P/E of 21.72 with recent quarterly revenue of $2,816,000,000 and net income of $245,000,000. The transaction occurs after the stock has appreciated 8.2% over 30 days and 4.2% over 90 days, providing context for the timing of this large disposal of equity.

CEO Davis J. E. executes 15 separate sales totaling 39,191 shares for $6,602,074.29 at DGX.

Davis J. E., CEO and President of Quest Diagnostics, executed 15 separate sales on 2025-04-02 totaling 39,191 shares for $6,602,074.29, representing a 23.5% reduction in his post-transaction holdings from 166,814 shares to 127,623 shares. The transactions were executed at prices ranging from $167.86 to $169.63, with a blended average of $168.46, while the stock currently trades at $164.18 — roughly 2.5% below the transaction prices. The scale and structure of this filing (15 separate transactions on a single day) and the magnitude of the position reduction warrant examination of whether this reflects a pre-planned capital deployment or another material business development at Quest Diagnostics.